Back
Halozyme Therapeutics, Inc. 10K Form
Buy
65
HALO
Halozyme Therapeutics, Inc.
Last Price:
$62.92
Seasonality Move:
17.07%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-07 | 10Q | HALO/Halozyme Therapeutics, Inc. Quarterly |
| 2023-11-06 | 10Q | HALO/Halozyme Therapeutics, Inc. Quarterly |
| 2023-08-08 | 10Q | HALO/Halozyme Therapeutics, Inc. Quarterly |
| 2023-05-09 | 10Q | HALO/Halozyme Therapeutics, Inc. Quarterly |
| 2022-11-08 | 10Q | HALO/Halozyme Therapeutics, Inc. Quarterly |
| 2022-08-09 | 10Q | HALO/Halozyme Therapeutics, Inc. Quarterly |
Receive HALO News And Ratings
See the #1 stock for the next 7 days that we like better than HALO
HALO Financial Statistics
Sales & Book Value
| Annual Sales: | $1B |
|---|---|
| Cash Flow: | $175.6M |
| Price / Cash Flow: | 13.12 |
| Annual Sales: | $4.29 |
| Price / Book: | 14.69 |
Profitability
| EPS (TTM): | 4.75740 |
|---|---|
| Net Income (TTM): | $595.5M |
| Gross Margin: | $784.9M |
| Return on Equity: | 139.43% |
| Return on Assets: | 27.69% |
Halozyme Therapeutics, Inc. Earnings Forecast
Key Halozyme Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 24 years for HALO is 77.30%.
-
The Selling, General & Administrative Expenses for HALO have been equal to 15.20% of Gross Profit Margin.
-
The Research & Development expenses have been 7.79% of Revenue.
-
The Interest Expense is 4.07% of Operating Income.
-
The Net Earning history of HALO is 43.74% of Total Revenues.
-
Per Share Earnings over the last 24 years have been positive in 12 years.
Halozyme Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | HALO |
| CUSIP: | 40637H |
| Website: | halozyme.com |
Debt
| Debt-to-Equity Ratio: | 3 |
|---|---|
| Current Ratio: | 1.59 |
| Quick Ratio: | 1.26 |
Price-to-Earnings
| Trailing P/E Ratio: | 18.35 |
|---|---|
| Forward P/E Ratio: | 7.9 |
HALO Technical Analysis vs Fundamental Analysis
Buy
65
Halozyme Therapeutics, Inc. (HALO)
is a Buy
Is Halozyme Therapeutics, Inc. a Buy or a Sell?
-
Halozyme Therapeutics, Inc. stock is rated a BuyThe current Halozyme Therapeutics, Inc. [HALO] share price is $62.95. The Score for HALO is 65, which is 30% above its historic median score of 50, and infers lower risk than normal.